Michael P.  Phalen net worth and biography

Michael Phalen Biography and Net Worth

Michael Phalen is an advisor in several companies. He was an Executive Vice President and President, Medical Surgery (MedSurg) for Boston Scientific and a member of its Executive Committee. In this role, he plans and executes Boston Scientific’s growth strategies for the Company’s Endoscopy, Urology/Women’s Health, and Neuromodulationbusinesses. Phalen also oversees Boston Scientific operations in Canada and Latin America.
Prior to assuming his current position in January 2012, Phalen was President of Boston Scientific International. He was responsible for planning and executing Boston Scientific’s international growth strategy.

Phalen joined Boston Scientific in 1988 and held various management positions of increasing responsibilities including Territory Manager, Product Manager, Regional Sales Manager, Group Product Manager, Director of Marketing, Vice President of Global Marketing and Senior Vice President and President of the company’s Endoscopy division.

Before joining Boston Scientific, Phalen held management positions with MD Technology, Kendall Healthcare and Pennwalt Pharmaceuticals. He earned a B.S. in General Science from Villanova University and an M.B.A. from Fairleigh Dickinson University.

How do I contact Michael P. Phalen?

The corporate mailing address for Mr. Phalen and other Boston Scientific executives is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. Boston Scientific can also be reached via phone at (508) 683-4000 and via email at [email protected]. Learn More on Michael P. Phalen's contact information.

Has Michael P. Phalen been buying or selling shares of Boston Scientific?

Michael P. Phalen has not been actively trading shares of Boston Scientific over the course of the past ninety days. Learn More on Michael P. Phalen's trading history.

Who are Boston Scientific's active insiders?

Boston Scientific's insider roster includes Kevin Ballinger (EVP), Supratim Bose (EVP), Daniel Brennan (CFO), Vance Brown (SVP), Arthur Butcher (EVP), Wendy Carruthers (SVP), Nelda Connors (Director), Keith Dawkins (EVP), Charles Dockendorff (Director), Jodi Eddy (SVP), Joseph Fitzgerald (EVP), Edward Ludwig (Director), Edward Ludwig (Director), Edward Mackey (EVP), Michael Mahoney (CEO), Ian Meredith (EVP), Jeffrey Mirviss (EVP), Jonathan Monson (CAO), Maulik Nanavaty (SVP), Scott Olson (SVP), Michael Phalen (EVP), David Pierce (EVP), Timothy Pratt (EVP), Desiree Ralls-Morrison (SVP), Meghan Scanlon (SVP), John Sorenson (SVP), Eric Thepaut (EVP), Xin Wang (SVP), and David Wichmann (Director). Learn More on Boston Scientific's active insiders.

Are insiders buying or selling shares of Boston Scientific?

During the last twelve months, insiders at the medical equipment provider sold shares 25 times. They sold a total of 714,289 shares worth more than $38,671,106.81. The most recent insider tranaction occured on April, 1st when EVP John Bradley Sorenson sold 16,351 shares worth more than $1,133,124.30. Insiders at Boston Scientific own 0.5% of the company. Learn More about insider trades at Boston Scientific.

Information on this page was last updated on 4/1/2024.

Michael P. Phalen Insider Trading History at Boston Scientific

See Full Table

Michael P. Phalen Buying and Selling Activity at Boston Scientific

This chart shows Michael P. Phalen's buying and selling at Boston Scientific by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Boston Scientific Company Overview

Boston Scientific logo
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Read More

Today's Range

Now: $73.30
Low: $72.91
High: $73.64

50 Day Range

MA: $67.68
Low: $65.75
High: $73.30

2 Week Range

Now: $73.30
Low: $48.35
High: $74.39

Volume

8,171,396 shs

Average Volume

6,143,995 shs

Market Capitalization

$107.54 billion

P/E Ratio

61.60

Dividend Yield

N/A

Beta

0.78